CTOT-45 (Lung Transplantation) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.
¿Cuál es la Condición que se está estudiando?
Lung Transplantation
¿Quién puede participar en el Estudio?
Adults ages 18+ who are on the list to receive a lung transplant.
For more information about who can join this study, please contact the study team at mailto: kathleen.lane@duke.edu.
Grupo etario
Adultos
¿Qué Implica?
If choose to join this study, you will:
- Get a random assignment (like a coin flip) to take the study drug or placebo (an inactive substance)
- Take the study drug or placebo once a month for five months after your lung transplant
- Realizar extracciones de sangre
- Have lung biopsy samples collected
- Have information collected from your medical record
- Have study visits for up to 3 years after your lung transplant
Detalles del Estudio
Título Completo
TARGETING INFLAMMATION AND ALLOIMMUNITY IN LUNG TRANSPLANT RECIPIENTS
WITH TOCILIZUMAB (ALL IN LUNG)
Investigador Principal
Matthew G. Hartwig, MD
Especialista en cirugía de trasplante pulmonar
Número de Protocolo
IRB:
PRO00113759
NCT:
NCT06033196
Fase
Phase
II
ClinicalTrials.gov
Ver en ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción